Leuprolide

An FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through hormonal suppression.

StrongWell-Studied

Always consult a qualified clinician

This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician

What is Leuprolide?

Leuprolide is a synthetic nonapeptide GnRH agonist that, when given continuously, paradoxically suppresses the reproductive hormone axis. After an initial stimulatory phase ('flare'), continuous administration downregulates GnRH receptors, dramatically reducing testosterone and estrogen levels. It is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.

Why People Talk About It

Prostate cancer treatment (androgen deprivation)

Strong

Endometriosis symptom management

Strong

Central precocious puberty treatment

Strong

IVF protocols (pituitary suppression)

Strong

How It Works

Leuprolide overwhelms the brain's reproductive hormone system. By constantly stimulating the GnRH receptor (instead of the normal pulsing pattern), it causes the receptor to shut down, which stops testosterone and estrogen production — useful for hormone-sensitive cancers and conditions.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Hot flashesDecreased libidoErectile dysfunctionBone density lossMood changes

Cautions

• Initial testosterone flare can worsen prostate cancer symptoms
• Long-term use causes bone density loss
• Cardiovascular risk with prolonged androgen deprivation
• Not for use in pregnancy

What We Don't Know

Well-characterized safety profile with decades of clinical use. Long-term bone and cardiovascular effects are monitored.

Published Research

33 studies

Effectiveness and Safety of Postoperative Medical Treatments Following Fertility-Preserving Surgery for Endometriosis: A Network Meta-Analysis

Meta-AnalysisPMID: 41017486

Pharmacologic Interventions for Endometriosis-Related Pain: A Systematic Review and Meta-analysis

Meta-AnalysisPMID: 40373315

GnRH analogues and dienogest for second line treatment of endometriosis-associated pain: a systematic review, meta-analysis, and network meta-analysis

Meta-AnalysisPMID: 40517509

Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies

Meta-AnalysisPMID: 39343637

The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis

Meta-AnalysisPMID: 40498278

The Effect of Hormonal Treatment on Ovarian Endometriomas: A Systematic Review and Meta-Analysis

Meta-AnalysisPMID: 38190884

Efficacy and safety of different subsequent therapies after fertility preserving surgery for endometriosis: A systematic review and network meta-analysis

Meta-AnalysisPMID: 37543781

Evaluation of safety and effectiveness of gestrinone in the treatment of endometriosis: a systematic review and meta-analysis

Meta-AnalysisPMID: 36434439

Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis

Meta-AnalysisPMID: 33398505

A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids

Meta-AnalysisPMID: 31127621

Efficacy of nafarelin in assisted reproductive technology: a meta-analysis

Meta-AnalysisPMID: 11212082

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

Meta-AnalysisPMID: 10744594

Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age

Randomized Controlled TrialPMID: 41274168

Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK

Randomized Controlled TrialPMID: 40140551

Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study

Randomized Controlled TrialPMID: 40016055

Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer

Randomized Controlled TrialPMID: 38451492

Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial

Randomized Controlled TrialPMID: 38161319

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Randomized Controlled TrialPMID: 38143206

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

Randomized Controlled TrialPMID: 37851874

LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer

Randomized Controlled TrialPMID: 37119051

Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer

Randomized Controlled TrialPMID: 38320501

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Randomized Controlled TrialPMID: 37833178

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer

Randomized Controlled TrialPMID: 37713020

Comparison of the effects of two different trigger strategies - dual (hCG + Leuprolide) versus hCG trigger - in antagonist non-donor IVF: a randomized controlled trial

Randomized Controlled TrialPMID: 37698459

Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial

Randomized Controlled TrialPMID: 34481017

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Randomized Controlled TrialPMID: 34459214

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

Randomized Controlled TrialPMID: 32469183

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone

Randomized Controlled TrialPMID: 30811282

Neoadjuvant Enzalutamide Prior to Prostatectomy

Randomized Controlled TrialPMID: 28151719

Testicular vs adrenal sources of hydroxy-androgens in prostate cancer

Randomized Controlled TrialPMID: 28663228

Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate

Clinical TrialPMID: 3918369

Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety

ReviewPMID: 35343198

Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer

ReviewPMID: 27826989

Always consult a qualified clinician